Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
Molly Gallagher, Andrew Sieben, Kristin Nelson, Alicia N.M. Kraay, Walter A. Orenstein, Ben Lopman, Andreas Handel, Katia Koelle
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologySars virusMedicineBetacoronavirusCoronavirusOutbreakInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesVaccine Coverage and Hesitancy